Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | NPY2R | P49146 | 1/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378423 | 0.77 | CNR2 (0.65) | — | |
| SCHEMBL12119 | 0.74 | NPY1R (0.57) | NPY1RHTTNPY2ROPRD1SIGMAR1 | |
| SCHEMBL2890670 | 0.74 | NPY1R (0.82) | NPY1RHTTNPY2RKDM4E | |
| SCHEMBL13379183 | 0.74 | NPY1R (0.82) | NPY1RHTTNPY2RKDM4E | |
| SCHEMBL2910215 | 0.72 | NPY1R (0.73) | NPY1RHTTNPY2RKDM4E | |
| SCHEMBL2889647 | 0.71 | NPY1R (0.77) | NPY1RHTTNPY2RKDM4E | |
| SCHEMBL13379182 | 0.71 | NPY1R (0.77) | NPY1RHTTNPY2RKDM4E | |
| SCHEMBL9171764 | 0.70 | NPY1R (0.53) | NPY1RHTTNPY2ROPRD1SIGMAR1 | |
| SCHEMBL2885978 | 0.69 | SIGMAR1 (0.54) | NPY1RHTTNPY2RSIGMAR1 | |
| SCHEMBL18407702 | 0.68 | NPY1R (0.50) | NPY1RHTTNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099673-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK SHARP & DOHME CORP. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099673-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | NPY1R 107/4885HTT 2944/4885NPY2R 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.